Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy

British Journal of Haematology

Volumn 147, Issue 3, 2009, Pages 308-318

  Sarosiek, Kristopher A ^a   Nechushtan, Hovav ^a   Lu, Xiaoqing ^a   Rosenblatt, Joseph D ^a,c   Lossos, Izidore S ^a,b  

^a Department of Molecular and Cellular Pharmacology ^*  (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diffuse large B cell lymphoma; Doxorubicin; Interleukin 4; Rituximab

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APOPTOSIS REGULATORY PROTEIN; DOXORUBICIN; INTERLEUKIN 4; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; RITUXIMAB;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL KILLING; CELL LINE; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; GERMINAL CENTER; HUMANS; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 70350014904     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07851.x     Document Type: Article

References (32)

1. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503 511.
2. Bannerji, R., Kitada, S., Flinn, I.W., Pearson, M., Young, D., Reed, J.C. Byrd, J.C. (2003) Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. Journal of Clinical Oncology, 21, 1466 1471.
3. Carey, G.B., Semenova, E., Qi, X. Keegan, A.D. (2007) IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Research, 17, 942 955.
4. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
5. Davis, R.E., Brown, K.D., Siebenlist, U. Staudt, L.M. (2001) Constitutive nuclear factor κ B activity is required for survival of activated b cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine, 194, 1861 1874.
6. Gagnon, V., Mathieu, I., Sexton, E., Leblanc, K. Asselin, E. (2004) AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecologic Oncology, 94, 785 795.
7. Gamen, S., Anel, A., Lasierra, P., Alava, M.A., Martinez-Lorenzo, M.J., Pineiro, A. Naval, J. (1997) Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Letters, 417, 360 364.
8. Gee, K., Kozlowski, M., Kryworuchko, M., Diaz-Mitoma, F. Kumar, A. (2001) Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells. Cellular Immunology, 211, 131 142.
9. Godal, R., Keilholz, U., Uharek, L., Letsch, A., Asemissen, A.M., Busse, A., Na, I.-K., Thiel, E. Scheibenbogen, C. (2006) Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood, 107, 3205 3211.
10. Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A. Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 3900 3908.
11. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121 3127.
12. Huang, J.Z., Sanger, W.G., Greiner, T.C., Staudt, L.M., Weisenburger, D.D., Pickering, D.L., Lynch, J.C., Armitage, J.O., Warnke, R.A., Alizadeh, A.A., Lossos, I.S., Levy, R. Chan, W.C. (2002) The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood, 99, 2285 2290.
13. Jinquan, T., Jacobi, H.H., Jing, C., Millner, A., Sten, E., Hviid, L., Anting, L., Ryder, L.P., Glue, C., Skov, P.S., Jarman, E., Lamberth, K., Malling, H.-J. Poulsen, L.K. (2003) CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells. Journal of Immunology, 171, 1722 1731.
14. Jones, E.A., Pringle, J.H., Angel, C.A. Rees, R.C. (2002) Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leukemia & Lymphoma, 43, 1313 1321.
15. van der Kolk, L.E., Grillo-López, A.J., Baars, J.W., Hack, C.E. van Oers, M.H.J. (2001) Complement activation plays a key role in the side-effects of rituximab treatment. British Journal of Haematology, 115, 807 811.
16. Kurtz, D.M., Tschetter, L.K., Allred, J.B., Geyer, S.M., Kurtin, P.J., Putnam, W.D., Rowland, K.M., Wiesenfeld, M., Soori, G.S., Tenglin, R.C., Bernath, A.M. Witzig, T.E. (2007) Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia & Lymphoma, 48, 1290 1298.
17. Lam, K.-P., Kühn, R. Rajewsky, K. (1997) In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell, 90, 1073 1083.
18. Lossos, I.S., Alizadeh, A.A., Eisen, M.B., Chan, W.C., Brown, P.O., Botstein, D., Staudt, L.M. Levy, R. (2000) Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proceedings of the National Academy of Sciences, 97, 10209 10213.
19. Lossos, I.S., Czerwinski, D.K., Wechser, M.A. Levy, R. (2002) Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia, 17, 789 795. (Pubitemid 36519378)
20. Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., Wechser, M.A., Tibshirani, R., Botstein, D. Levy, R. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine, 350, 1828 1837.
21. Lu, X., Nechushtan, H., Ding, F., Rosado, M.F., Singal, R., Alizadeh, A.A. Lossos, I.S. (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood, 105, 2924 2932.
22. Lu, X., Chen, J., Sasmono, R.T., Hsi, E.D., Sarosiek, K.A., Tiganis, T. Lossos, I.S. (2007) T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Molecular and Cellular Biology, 27, 2166 2179.
23. Lu, X., Malumbres, R., Shields, B., Jiang, X., Sarosiek, K.A., Natkunam, Y., Tiganis, T. Lossos, I.S. (2008) PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood, 112, 4098 4108.
24. van Meerten, T., van Rijn, R.S., Hol, S., Hagenbeek, A. Ebeling, S.B. (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical Cancer Research, 12, 4027 4035.
25. Natkunam, Y., Lossos, I.S., Taidi, B., Zhao, S., Lu, X., Ding, F., Hammer, A.S., Marafioti, T., Byrne, Jr., G.E., Levy, S., Warnke, R.A. Levy, R. (2005) Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood, 105, 3979 3986.
26. Natkunam, Y., Farinha, P., Hsi, E.D., Hans, C.P., Tibshirani, R., Sehn, L.H., Connors, J.M., Gratzinger, D., Rosado, M., Zhao, S., Pohlman, B., Wongchaowart, N., Bast, M., Avigdor, A., Schiby, G., Nagler, A., Byrne, G.E., Levy, R., Gascoyne, R.D. Lossos, I.S. (2008) LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. Journal of Clinical Oncology, 26, 447 454.
27. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. Staudt, L.M. & the Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 1937 1947.
28. Taylor, C., Grogan, T. Salmon, S. (1990) Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood, 75, 1114 1118.
29. Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R. Anderson, K.C. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Journal of Immunotherapy, 1991, 24.
30. Uddin, S., Hussain, A.R., Siraj, A.K., Manogaran, P.S., Al-Jomah, N.A., Moorji, A., Atizado, V., Al-Dayel, F., Belgaumi, A., El-Solh, H., Ezzat, A., Bavi, P. Al-Kuraya, K.S. (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 108, 4178 4186.
31. Weng, W.K. Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 98, 1352 1357.
32. Wilkinson, R.W., Lee-MacAry, A.E., Davies, D., Snary, D. Ross, E.L. (2001) Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. Journal of Immunological Methods, 258, 183 191.